Driver clocks over 70 mph past elementary school: Sheriff
The Douglas County Sheriff's Office posted about the alleged speeder on Facebook, saying the driver clocked 73 mph in a 40-mph zone. The sheriff's office said this was right past an elementary school.
Going 45 in a school zone is cause for jail time
'The driver claimed he was taking a passenger to get a bus pass… at this rate, he might need one himself if the tickets keep piling up,' the sheriff's office said.
This comes during 'Colorado's deadliest days,' which mark the deadliest days in the summer for driving. In 2024, there were 71 deadly crashes in the stretch between Memorial Day to Labor Day.
'Slow down. Obey the speed limit. Drive smart, it's not worth it,' the sheriff's office said on a Facebook post.
In Colorado, fines for speeding 1-24 mph over the speed limit vary from $35-$200. However, driving over 25 mph can have a minimum sentence of 10 days in jail and a maximum sentence of one year.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Arrests made in Gwinnett park shootings, 1 linked to gang activity
Four people have now been arrested in connection with two separate shootings at Briscoe Park in Snellville over Memorial Day weekend that left families running for cover. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] The latest arrest came Thursday when Snellville Police charged 18-year-old Nasear Johnson with five counts of aggravated assault for the Saturday night shooting that injured five teenagers. Two other suspects were arrested in June in connection with the same incident. Joshua Zere, 17, was arrested June 11 and charged as a party to a crime for aggravated assault along with gang-related charges. Eric Meier-Harris, 17, was arrested June 12 on five counts of aggravated assault. Court testimony on July 23 for Zere revealed the Saturday night violence stemmed from gang rivalry between competing groups. Police say rival gangs had an argument at the birthday party that led to a shootout. Paul Williams was taking family photos when gunfire erupted that Saturday night and happened to be near where more than 100 people were at the party. 'Stray bullets were flying. My kids could have got hit. I could have got hit. My wife could have got hit,' Williams said. Williams was near the gazebo with eight children when bullets started flying just 200 feet away. 'We run. We got to the car. My kids got in the car. My kids are crying. We are rushing into the car,' Williams said. Investigators collected more than 30 shell casings from multiple caliber weapons including rifles. Five teenagers between 14 and 17 years old were shot and hospitalized. The next afternoon brought another shooting at the same park when 32-year-old Christopher Gaston allegedly shot one man near the baseball fields while families watched children play. Police have not released a motive for that shooting. He turned himself voluntarily on July 22, according to court records. Since the incidents, Snellville has increased patrols from police and private security. City leaders are also exploring lighting and security camera improvements at the park. [SIGN UP: WSB-TV Daily Headlines Newsletter]
Business Wire
4 hours ago
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
Yahoo
4 hours ago
- Yahoo
Police seeking security footage after rash of arsons near Irving Park
PORTLAND, Ore. (KOIN) — Police are asking for help to identify the suspect in multiple arsons near Irving Park over the last week. Portland police are asking anyone living near Irving Park to review their security camera footage from July 20 and July 27, as they may have video footage of an arson suspect. The first arsons happened on July 20 and included a shed in the 700 block of Northeast Fremont Street, a trailer parked in the 3100 block of Northeast 8th Street, and a garage door in the 3600 block of Northeast 7th Street. On July 27, police said that several more arsons happened, including a fire that damaged a fence and shed in the 3900 block of Northeast Martin Luther King Jr Boulevard and one that damaged a vehicle in the 3800 block of Northeast 6th Avenue. Authorities said they are focusing on the area between North Williams Avenue and Northeast 15th Avenue and between Northeast Stanton Street and Northeast Shaver Street. Police are asking any residents living in that area with security footage between the hours of 3 a.m. and 5 a.m. on July 20 and between 9 p.m. and 11 p.m. on July 27 to share the unedited footage with them online. Anyone with further information about the case is asked to contact Portland police. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
